ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- HER2 Positive Gastric Cancer
- HER2 Positive Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Metastatic Cancer
- Solid Tumor
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04319757
- Collaborators
- Not Provided
- Investigators
- Study Director: Michael Kurman, MD Acepodia Biotech Inc.